Biotech | March 23, 2022
GMP certification for Exothera further extends its viral vector manufacturing capacity
The expansion makes Exothera one of the largest viral vector facilities in Europe
The expansion makes Exothera one of the largest viral vector facilities in Europe
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
Enables millions of Indians to monitor their vitals without the need of any additional device
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Successful proposals will secure fully funded postdoctoral research positions
The facility will enable research initiatives in analytical chemistry, biopharmaceuticals, and life sciences
The centre will initially employ 170 engineers, bringing the total number of Boston Scientific’s R&D employees in India to more than 300
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
Deploying solutions like Uniphore’s U-Self Serve and U-Assist with SpinSci’s Patient Engage and Patient Assist is an important step forward in creating frictionless patient experiences
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
Subscribe To Our Newsletter & Stay Updated
